What do forensic analysts consider relevant to their decision making?
نویسندگان
چکیده
منابع مشابه
Biosimilars: what do patients need to consider?
A view from the EULAR Standing Committee of People with Arthritis/Rheumatism in Europe (SCPARE) on some of the issues that patients might wish to consider about biosimilars in shared decision-making discussions with their rheumatologist. The paper also points to the need for more information on biosimilars being made available in lay language.
متن کاملWhat do Analysts’ Forecasts Reveal about Analysts’ ‘Other’ Information? †
Analysts often provide forecasts of one-year ahead earnings, earnings two-year ahead, as well as long-term earnings growth rates. In our attempts to understand the properties of these contemporaneous multi-period earnings forecasts, we begin by examining whether analysts’ earnings forecasts can be described using the linear information dynamics (LID). We find that LID is an appropriate descript...
متن کاملWhat do Analysts ’ Forecasts Reveal about Analysts ’ Private Information ?
Analysts often provide forecasts of one-year ahead earnings, earnings two-year ahead, as well as long-term earnings growth rates. In our attempts to understand the properties of these contemporaneous multi-period earnings forecasts, we begin by examining whether analysts’ earnings forecasts can be described using the linear information dynamics (LID). We find that LID is an appropriate descript...
متن کاملWhat Do Analysts Do ? Investor Decision and the Analyst Remuneration Mode
This paper questions the interaction between security analysts and institutional investors. We focus particularly on the role of analyst remuneration mode in investor decision. To do so, we propose a model in which the investor decides to trade or not to trade regarding the analyst recommendation. First, with a commission-based salary, the analyst is interested in the volume of transactions. Th...
متن کاملBiosimilar therapeutics—what do we need to consider?
Patents for the first generation of approved biopharmaceuticals have either expired or are about to expire. Thus the market is opening for generic versions, referred to as 'biosimilars' (European Union) or 'follow-on protein products' (United States). Healthcare professionals need to understand the critical issues surrounding the use of biosimilars to make informed treatment decisions.The compl...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Science & Justice
سال: 2019
ISSN: 1355-0306
DOI: 10.1016/j.scijus.2019.04.005